The company had initially said it expected a price range of between $8 and $10, but the IPO will now go off at $6 per share.
The company said that a UK court today agreed to sanction its plan to float in the US, conditional upon the execution of the Underwriter Agreement by Osmetech and the underwriters before 7 a.m. BST, Friday.
Osmetech expects to raise proceeds of around $35 million from the offering, which part of a plan to set up its headquarters in the US.
A majority of Osmetech's shareholders voted in favor of the plan to float in the US, change the firm's name, and relocate its headquarters to California.
The British molecular diagnostics firm intends to raise around $40 million in a US IPO and will be based in the US as a wholly-owned subsidiary of GenMark Diagnostics.
BG has filed for an IPO in the US, a few years after withdrawing an effort to float on the Euronext Amsterdam Exchange.
Med BioGene said that the purpose of the rights plan is to provide sufficient time to its board and shareholders to assess any unsolicited takeover bids.
The Canadian firm, which already floats on the Toronto Stock Exchange, is gearing up for the launch of its LungExpress Dx product in the US.
RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.
The proceeds will support commercialization of the company's gene expression-based assay for early-stage non-small-cell lung cancer.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.